TIPRANAVIR (Boehringer-Ingelheim)
An all-new protease inhibitor (PI)

What’s the hope?
It promises punch in patients with PI resistance.

How can you get it?
Two Phase III trials and an open-label safety study are now enrolling. Search “tipranavir” at www.clinicaltrials.gov or call 800.344.4095 x6215.

CAPRAVIRINE (Agouron/Pfizer)
A second-generation NNRTI (non-nuke)

What’s the hope?
It could aid HIVers with Sustiva-Viramune cross-resistance.

How can you get it?
Two trials are now enrolling. Search “capravirine” at www.clinicaltrials.gov or call 858.622.8035 for details.

PRO 542 (Progenics)
One of a new class of drugs called entry inhibitors

What’s the hope?
A once-weekly injection could seriously whack HIV—without the side effects of today’s drugs.

How can you get it?
A trial for HIVers with failing regimens is enrolling. Search “PRO 542” at www.clinicaltrials.gov for details.

And periodically visit www.clinicaltrials.gov to search trials for new drugs like NNRTI TMC 125; PI TMC 114; and entry inhibitors SCH-C and TNX-355. (PS. Drugs get snazzy names only after they’re approved.)